Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Whole Cell Cholera Vaccine by End User (Pediatrics, Adults): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03456

Pages: NA

Charts: NA

Tables: NA

Cholera is a chronic disease associated with diarrhea and immediate treatment is essential as death is inevitable if the disease is left untreated. Cholera is an acute infection caused by the bacterium Vibrio cholerae. It is anticipated to be a global threat to public health especially in regions that lack social development. Thus, oral cholera vaccines are utilized to supplement the management of the disease globally.

The factors that fuel the growth of the global whole cell cholera vaccine (recombinant B-subunit) market are rising incidence of cholera among people in endemic regions along with a lack of sanitation and hygiene in certain countries. In addition, according to WHO in 2015, cholera was responsible for 21,000 to 143,000 deaths globally. However, longer timelines required to produce vaccines and high monetary inputs associated with the same restrain the market growth. But recent outbreaks of cholera in certain countries will offer lucrative opportunities for the market growth.

The market is segmented based on end user and region. Based on end user, the market is segmented into pediatrics and adults. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players that operate in the market are SBL Vaccine, PaxVax, Inc., Valneva SE, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur, AstraZeneca Plc. (Medimmune, LLC.), and Serum Institute of India Pvt. Ltd.

Key Benefits

  • The study provides an in-depth analysis of the global whole cell cholera vaccine (recombinant B-subunit) market with current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis to enable stakeholders to capitalize on prevailing market opportunities.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
  • By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

 Key Market Segments

  • By End User
    • Pediatrics
    • Adults
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Russia
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Argentina
      • Rest of LAMEA

 
Key Market Players

  • GlaxoSmithKline Plc.,
  • PaxVax, Inc.,
  • AstraZeneca Plc. (Medimmune, LLC.),
  • Serum Institute of India Pvt. Ltd.
  • Johnson & Johnson,
  • SBL Vaccine,
  • Sanofi Pasteur,
  • Pfizer Inc.,
  • Valneva SE,
  • Merck & Co., Inc.,

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: WHOLE CELL CHOLERA VACCINE BY END USER MARKET, BY END USER

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By End User

    • 4.2. Pediatrics

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Adults

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: WHOLE CELL CHOLERA VACCINE BY END USER MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By End User

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Whole Cell Cholera Vaccine By End User Market

        • 5.2.4.1. Market Size and Forecast, By End User

      • 5.2.5. Canada Whole Cell Cholera Vaccine By End User Market

        • 5.2.5.1. Market Size and Forecast, By End User

      • 5.2.6. Mexico Whole Cell Cholera Vaccine By End User Market

        • 5.2.6.1. Market Size and Forecast, By End User

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By End User

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Whole Cell Cholera Vaccine By End User Market

        • 5.3.4.1. Market Size and Forecast, By End User

      • 5.3.5. Germany Whole Cell Cholera Vaccine By End User Market

        • 5.3.5.1. Market Size and Forecast, By End User

      • 5.3.6. Italy Whole Cell Cholera Vaccine By End User Market

        • 5.3.6.1. Market Size and Forecast, By End User

      • 5.3.7. Spain Whole Cell Cholera Vaccine By End User Market

        • 5.3.7.1. Market Size and Forecast, By End User

      • 5.3.8. UK Whole Cell Cholera Vaccine By End User Market

        • 5.3.8.1. Market Size and Forecast, By End User

      • 5.3.9. Russia Whole Cell Cholera Vaccine By End User Market

        • 5.3.9.1. Market Size and Forecast, By End User

      • 5.3.10. Rest Of Europe Whole Cell Cholera Vaccine By End User Market

        • 5.3.10.1. Market Size and Forecast, By End User

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By End User

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Whole Cell Cholera Vaccine By End User Market

        • 5.4.4.1. Market Size and Forecast, By End User

      • 5.4.5. Japan Whole Cell Cholera Vaccine By End User Market

        • 5.4.5.1. Market Size and Forecast, By End User

      • 5.4.6. India Whole Cell Cholera Vaccine By End User Market

        • 5.4.6.1. Market Size and Forecast, By End User

      • 5.4.7. South Korea Whole Cell Cholera Vaccine By End User Market

        • 5.4.7.1. Market Size and Forecast, By End User

      • 5.4.8. Australia Whole Cell Cholera Vaccine By End User Market

        • 5.4.8.1. Market Size and Forecast, By End User

      • 5.4.9. Thailand Whole Cell Cholera Vaccine By End User Market

        • 5.4.9.1. Market Size and Forecast, By End User

      • 5.4.10. Malaysia Whole Cell Cholera Vaccine By End User Market

        • 5.4.10.1. Market Size and Forecast, By End User

      • 5.4.11. Indonesia Whole Cell Cholera Vaccine By End User Market

        • 5.4.11.1. Market Size and Forecast, By End User

      • 5.4.12. Rest of Asia Pacific Whole Cell Cholera Vaccine By End User Market

        • 5.4.12.1. Market Size and Forecast, By End User

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By End User

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Whole Cell Cholera Vaccine By End User Market

        • 5.5.4.1. Market Size and Forecast, By End User

      • 5.5.5. South Africa Whole Cell Cholera Vaccine By End User Market

        • 5.5.5.1. Market Size and Forecast, By End User

      • 5.5.6. Saudi Arabia Whole Cell Cholera Vaccine By End User Market

        • 5.5.6.1. Market Size and Forecast, By End User

      • 5.5.7. UAE Whole Cell Cholera Vaccine By End User Market

        • 5.5.7.1. Market Size and Forecast, By End User

      • 5.5.8. Argentina Whole Cell Cholera Vaccine By End User Market

        • 5.5.8.1. Market Size and Forecast, By End User

      • 5.5.9. Rest of LAMEA Whole Cell Cholera Vaccine By End User Market

        • 5.5.9.1. Market Size and Forecast, By End User

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. SBL Vaccine,

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. PaxVax, Inc.,

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Valneva SE,

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. GlaxoSmithKline Plc.,

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Johnson And Johnson,

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Merck And Co., Inc.,

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. Pfizer Inc.,

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Sanofi Pasteur,

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. AstraZeneca Plc. (Medimmune, LLC.),

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Serum Institute Of India Pvt. Ltd.

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL WHOLE CELL CHOLERA VACCINE BY END USER MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL WHOLE CELL CHOLERA VACCINE BY END USER MARKET FOR PEDIATRICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL WHOLE CELL CHOLERA VACCINE BY END USER MARKET FOR ADULTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL WHOLE CELL CHOLERA VACCINE BY END USER MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. NORTH AMERICA WHOLE CELL CHOLERA VACCINE BY END USER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. NORTH AMERICA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 7. U.S. WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 8. CANADA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 9. MEXICO WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. EUROPE WHOLE CELL CHOLERA VACCINE BY END USER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. EUROPE WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 12. FRANCE WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 13. GERMANY WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 14. ITALY WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. SPAIN WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. UK WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. RUSSIA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. REST OF EUROPE WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. ASIA-PACIFIC WHOLE CELL CHOLERA VACCINE BY END USER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. ASIA-PACIFIC WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. CHINA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. JAPAN WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. INDIA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. SOUTH KOREA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. AUSTRALIA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. THAILAND WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. MALAYSIA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. INDONESIA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. REST OF ASIA PACIFIC WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. LAMEA WHOLE CELL CHOLERA VACCINE BY END USER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. LAMEA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. BRAZIL WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. SOUTH AFRICA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. SAUDI ARABIA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. UAE WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. ARGENTINA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. REST OF LAMEA WHOLE CELL CHOLERA VACCINE BY END USER, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. SBL VACCINE,: KEY EXECUTIVES
  • TABLE 39. SBL VACCINE,: COMPANY SNAPSHOT
  • TABLE 40. SBL VACCINE,: OPERATING SEGMENTS
  • TABLE 41. SBL VACCINE,: PRODUCT PORTFOLIO
  • TABLE 42. SBL VACCINE,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 43. PAXVAX, INC.,: KEY EXECUTIVES
  • TABLE 44. PAXVAX, INC.,: COMPANY SNAPSHOT
  • TABLE 45. PAXVAX, INC.,: OPERATING SEGMENTS
  • TABLE 46. PAXVAX, INC.,: PRODUCT PORTFOLIO
  • TABLE 47. PAXVAX, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 48. VALNEVA SE,: KEY EXECUTIVES
  • TABLE 49. VALNEVA SE,: COMPANY SNAPSHOT
  • TABLE 50. VALNEVA SE,: OPERATING SEGMENTS
  • TABLE 51. VALNEVA SE,: PRODUCT PORTFOLIO
  • TABLE 52. VALNEVA SE,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 53. GLAXOSMITHKLINE PLC.,: KEY EXECUTIVES
  • TABLE 54. GLAXOSMITHKLINE PLC.,: COMPANY SNAPSHOT
  • TABLE 55. GLAXOSMITHKLINE PLC.,: OPERATING SEGMENTS
  • TABLE 56. GLAXOSMITHKLINE PLC.,: PRODUCT PORTFOLIO
  • TABLE 57. GLAXOSMITHKLINE PLC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 58. JOHNSON AND JOHNSON,: KEY EXECUTIVES
  • TABLE 59. JOHNSON AND JOHNSON,: COMPANY SNAPSHOT
  • TABLE 60. JOHNSON AND JOHNSON,: OPERATING SEGMENTS
  • TABLE 61. JOHNSON AND JOHNSON,: PRODUCT PORTFOLIO
  • TABLE 62. JOHNSON AND JOHNSON,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 63. MERCK AND CO., INC.,: KEY EXECUTIVES
  • TABLE 64. MERCK AND CO., INC.,: COMPANY SNAPSHOT
  • TABLE 65. MERCK AND CO., INC.,: OPERATING SEGMENTS
  • TABLE 66. MERCK AND CO., INC.,: PRODUCT PORTFOLIO
  • TABLE 67. MERCK AND CO., INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 68. PFIZER INC.,: KEY EXECUTIVES
  • TABLE 69. PFIZER INC.,: COMPANY SNAPSHOT
  • TABLE 70. PFIZER INC.,: OPERATING SEGMENTS
  • TABLE 71. PFIZER INC.,: PRODUCT PORTFOLIO
  • TABLE 72. PFIZER INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 73. SANOFI PASTEUR,: KEY EXECUTIVES
  • TABLE 74. SANOFI PASTEUR,: COMPANY SNAPSHOT
  • TABLE 75. SANOFI PASTEUR,: OPERATING SEGMENTS
  • TABLE 76. SANOFI PASTEUR,: PRODUCT PORTFOLIO
  • TABLE 77. SANOFI PASTEUR,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: KEY EXECUTIVES
  • TABLE 79. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: COMPANY SNAPSHOT
  • TABLE 80. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: OPERATING SEGMENTS
  • TABLE 81. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: PRODUCT PORTFOLIO
  • TABLE 82. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 84. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 85. SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
  • TABLE 86. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 87. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL WHOLE CELL CHOLERA VACCINE BY END USER MARKET SEGMENTATION
  • FIGURE 2. GLOBAL WHOLE CELL CHOLERA VACCINE BY END USER MARKET
  • FIGURE 3. SEGMENTATION WHOLE CELL CHOLERA VACCINE BY END USER MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN WHOLE CELL CHOLERA VACCINE BY END USER MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALWHOLE CELL CHOLERA VACCINE BY END USER MARKET
  • FIGURE 11. WHOLE CELL CHOLERA VACCINE BY END USER MARKET SEGMENTATION, BY BY END USER
  • FIGURE 12. WHOLE CELL CHOLERA VACCINE BY END USER MARKET FOR PEDIATRICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. WHOLE CELL CHOLERA VACCINE BY END USER MARKET FOR ADULTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 18. COMPETITIVE DASHBOARD
  • FIGURE 19. COMPETITIVE HEATMAP: WHOLE CELL CHOLERA VACCINE BY END USER MARKET
  • FIGURE 20. TOP PLAYER POSITIONING, 2024
  • FIGURE 21. SBL VACCINE,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 22. SBL VACCINE,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 23. SBL VACCINE,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 24. PAXVAX, INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 25. PAXVAX, INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 26. PAXVAX, INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 27. VALNEVA SE,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. VALNEVA SE,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. VALNEVA SE,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. GLAXOSMITHKLINE PLC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. GLAXOSMITHKLINE PLC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. GLAXOSMITHKLINE PLC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. JOHNSON AND JOHNSON,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. JOHNSON AND JOHNSON,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. JOHNSON AND JOHNSON,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. MERCK AND CO., INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. MERCK AND CO., INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. MERCK AND CO., INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. PFIZER INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. PFIZER INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. PFIZER INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. SANOFI PASTEUR,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. SANOFI PASTEUR,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. SANOFI PASTEUR,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. ASTRAZENECA PLC. (MEDIMMUNE, LLC.),: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Whole Cell Cholera Vaccine by End User

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved